Coherus Oncology offers extreme asymmetric upside from LOQTORZI growth and two immuno-oncology catalysts, but cash burn, dilution, and binary clinical risk make CHRS a speculative recovery play.
Overview
Coherus BioSciences, operating as Coherus Oncology, has completed a strategic transformation from a biosimilar developer into a focused commercial-stage immuno-oncology company. After divesting Cimerli, Yusimry, and Udenyca, **100% of continuing product revenue now comes from LOQTORZI**, the only FDA-approved and available U.S. therapy for advanced NPC and the sole Category 1 Preferred NCCN option in first-line combination treatment. Q2 2026 continuing revenue increased 39.54% year over year to $14.31 million, while LOQTORZI revenue rose 15.25% sequentially to $13.60 million. Gross margin improved to 70.35%, and the operating loss narrowed to $32.33 million, although the company remained unprofitable and used $119.98 million of operating cash in the first half. Management reaffirmed 2026 LOQTORZI revenue guidance of $57 million-$62 million and targets a $175 million annualized NPC run rate by 2028. Valuation is depressed at approximately 3.5x trailing P/S versus an 11.3x U.S. biotechnology peer average, but the discount reflects financing and clinical risks. **The near-term catalysts are second-half 2026 casdozokitug and tagmokitug readouts, particularly the October datasets.** The August refinancing extends debt maturity to 2031 but carries a current 10.90% rate and minimum-cash covenants.